Chipscreen(688321)2025-02-27 10:40Financial Performance - Total revenue for 2024 reached CNY 657.95 million, a year-on-year increase of 25.63%[7] - Net profit attributable to the parent company was CNY -114.57 million, a decrease of 228.97% compared to the previous year[7] - The company recorded a net profit of CNY -205.28 million after excluding non-recurring gains and losses, a reduction in loss of 5.62% year-on-year[7] - The basic earnings per share decreased to CNY -0.2808, down 229.04% from CNY 0.2176 in the previous year[4] - The company’s weighted average return on net assets decreased by 12.44 percentage points to -6.97%[4] - The company’s net assets attributable to the parent company decreased by 7.53% to CNY 1,581.10 million[5] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,250.90 million, an increase of 1.49% from the beginning of the period[5] Impairments and Provisions - The company decided not to submit a listing application for a specific drug, leading to a full impairment provision of approximately CNY 90 million, which reduced the total profit for 2024[9] Licensing and Agreements - The company terminated the exclusive licensing and joint marketing agreement with Zhejiang Haizheng Pharmaceutical, resulting in a one-time recognition of approximately CNY 65 million in unamortized licensing fees[8] Investment Income - The company achieved a one-time investment income of CNY 289.04 million from a subsidiary that was no longer included in the consolidated financial statements[10]